Conservative MP Dean Del Mastro has raised the prospect of government regulation of online anonymity, arguing that Parliament should address the issue of forcing people to identify themselves before posting comments online.
News
Supreme Court To Hear Case Challenging Constitutionality of Privacy Law
The Supreme Court of Canada yesterday granted leave for what could be the most important privacy case in years as it addresses “whether the Personal Information Protection Act [Alberta’s private sector privacy law] is contrary to s.2(b) of the Charter and if so, whether it constitutes a reasonable limit in […]
Reactions to the CRTC’s Bell – Astral Decision
Several must-read posts and articles on the CRTC’s Bell – Astral decision from over the weekend from David Ellis, Dwayne Winseck, and Steven Chase of the Globe and Mail.
This Is Not Your Parent’s CRTC: Commission Rejects the Bell – Astral Deal
The CRTC identified multiple problems with the Bell bid (radio, tangible benefits, lack of evidence that bigger is better online), but the conclusion says it all:
The Commission finds that BCE has not discharged its burden and demonstrated that, on balance, this transaction is in the public interest. The benefits proposed would advantage BCE and its services, but the Commission is not persuaded that the transaction would provide significant and unequivocal benefits to the Canadian broadcasting system and to Canadians sufficient to outweigh the concerns described above.
While demonstrating that the transaction is in the public interest is always the language used in these proceedings, the CRTC has in the past focused on the tangible benefits package (ie. the multi-million dollar payments to creator groups) as the primary proxy for public interest. No longer. The CRTC’s focus today is unequivocally on the broader public interest with consumer impact the leading concern.
The $2 Billion Big Pharma Giveaway in CETA: Can the Government Ignore Its Own Internal Analysis?
For months, big pharmaceutical companies (known as Rx&D) and civil society/the generic pharmaceutical industry have been battling over the issue. Each has released public opinion surveys that purport to demonstrate support for their position (Rx&D, civil society). More important has been a study that concluded that the proposed reforms could add billions to annual Canadian health care costs along with reports that show that the large pharmaceutical companies failed to meet research and development commitments the last time the Canadian government acquiesced to patent reform demands.
While Rx&D sought to downplay those studies (as did the government, which described these concerns as a myth), it now faces an internal government study conducted by Industry Canada and Health Canada that placed the costs of CETA patent reform as high as $2 billion per year. The $2 billion cost would significantly decrease the government’s claims of likely economic gains from CETA and heighten provincial opposition, since the costs will be offloaded to provincial health care budgets.
Recent Posts
TIFF Removes October 7th Documentary Film From Schedule Citing Implausible Copyright Clearance Concerns From Hamas Terror Footage 
Carney’s Digital Recalibration: How the Government is Trending Away from Justin Trudeau’s Digital Policy 
Let Competition Be the Guide: Why the Government and CRTC Got It Right on Wholesale Fibre Broadband Access 
Commentary: Ensuring the Sovereignty and Security of Canadian Health Data 
The Law Bytes Podcast Law Society of Ontario CPD Professionalism Pack
